Cerhan James R, Fredericksen Zachary S, Wang Alice H, Habermann Thomas M, Kay Neil E, Macon William R, Cunningham Julie M, Shanafelt Tait D, Ansell Stephen M, Call Timothy G, Witzig Thomas E, Slager Susan L, Liebow Mark
Int J Mol Epidemiol Genet. 2011;2(2):95-113. Epub 2011 Apr 5.
We present the design features and implementation of a clinic-based case-control study on the molecular epidemiology of lymphoma conducted at the Mayo Clinic (Rochester, Minnesota, USA), and then assess the internal and external validity of the study. Cases were newly diagnosed lymphoma patients from Minnesota, Iowa and Wisconsin seen at Mayo and controls were patients from the same region without lymphoma who had a pre-scheduled general medical examination, frequency matched on age, sex and residence. Overall response rates were 67% for cases and 70% for controls; response rates were lower for cases and controls over age 70 years, cases with more aggressive disease, and controls from the local area, although absolute differences were modest. Cases and controls were well-balanced on age, sex, and residence characteristics. Demographic and disease characteristics of NHL cases were similar to population-based cancer registry data. Control distributions were similar to population-based data on lifestyle factors and minor allele frequencies of over 500 SNPs, although smoking rates were slightly lower. Associations with NHL in the Mayo study for smoking, alcohol use, family history of lymphoma, autoimmune disease, asthma, eczema, body mass index, and single nucleotide polymorphisms in TNF (rs1800629), LTA (rs909253), and IL10 (rs1800896) were at a magnitude consistent with estimates from pooled studies in InterLymph, with history of any allergy the only directly discordant result in the Mayo study. These data suggest that this study should have strong internal and external validity. This framework may be useful to others who are designing a similar study.
我们介绍了在美国明尼苏达州罗切斯特市梅奥诊所开展的一项基于临床的淋巴瘤分子流行病学病例对照研究的设计特点与实施情况，然后评估了该研究的内部和外部有效性。病例为在梅奥诊所就诊的来自明尼苏达州、爱荷华州和威斯康星州的新诊断淋巴瘤患者，对照为来自同一地区且未患淋巴瘤的患者，这些对照是预先安排进行普通医学检查的，在年龄、性别和居住地方面进行了频率匹配。病例的总体应答率为67%，对照为70%；70岁以上的病例和对照、疾病侵袭性更强的病例以及来自当地的对照的应答率较低，尽管绝对差异不大。病例和对照在年龄、性别和居住特征方面平衡良好。非霍奇金淋巴瘤（NHL）病例的人口统计学和疾病特征与基于人群的癌症登记数据相似。对照的分布与基于人群的生活方式因素数据以及500多个单核苷酸多态性（SNP）的次要等位基因频率相似，尽管吸烟率略低。梅奥研究中NHL与吸烟、饮酒、淋巴瘤家族史、自身免疫性疾病、哮喘、湿疹、体重指数以及肿瘤坏死因子（TNF，rs1800629）、淋巴毒素α（LTA，rs909253）和白细胞介素10（IL10，rs1800896）中的单核苷酸多态性的关联程度与InterLymph汇总研究的估计值一致，在梅奥研究中唯一直接不一致的结果是任何过敏史。这些数据表明该研究应具有较强的内部和外部有效性。这个框架可能对其他正在设计类似研究的人有用。
